Merck & Co., Inc. (MRK)

NYSE - Nasdaq Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

86.12

-0.52

(-0.60%)

At close: 04:04PM EDT

86.12

0.00

(0.00%)

After hours:

07:55PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	86.64
Open	87.25
Bid	81.32 x 800
Ask	91.46 x 800
Day's Range	86.10 - 87.61
52 Week Range	71.50 - 95.72
Volume	9,035,613
Avg. Volume	8,173,601

Market Cap	218.166B
Beta (5Y Monthly)	0.34
PE Ratio (TTM)	13.15
EPS (TTM)	6.55
Earnings Date	Oct 27, 2022
Forward Dividend & Yield	2.76 (3.20%)
Ex-Dividend Date	Sep 14, 2022
1y Target Est	100.90

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Near Fair Value

8% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for MRK

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Merck & Company, Inc.
Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Rating
Fair Value
Economic Moat
13 days agoMorningstar

All

Simply Wall St.
With Merck & Co., Inc. (NYSE:MRK) It Looks Like You'll Get What You Pay For
There wouldn't be many who think Merck & Co., Inc.'s ( NYSE:MRK ) price-to-earnings (or "P/E") ratio of 13.1x is worth...
- More Unpleasant Surprises Could Be In Store For Uniserve Communications Corporation's (CVE:USS) Shares After Tumbling 29%
  Simply Wall St.
- Is It Time To Consider Buying Universal Logistics Holdings, Inc. (NASDAQ:ULH)?
  Simply Wall St.
Motley Fool
What This News Means for Merck
In combination with Roche's (OTC: RHHBY) bevacizumab (Avastin), Merck's (NYSE: MRK) oncology medicine -- co-owned with AstraZeneca (NASDAQ: AZN) and known as Lynparza -- received the nod from China's National Medical Products Administration (NMPA) to treat patients with a form of advanced ovarian cancer. What led the NMPA to green-light the treatment combo?
Business Wire
U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit
RAHWAY, N.J., September 29, 2022--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Court of Appeals for the Federal Circuit ruled in favor of the company in a patent challenge brought by Mylan Pharmaceuticals, Inc. (now Viatris) related to sitagliptin dihydrogen phosphate, an active ingredient in JANUVIA® (sitagliptin), JANUMET® (sitagliptin and metformin hydrochloride) and JANUMET® XR (sitagliptin and metformin hydrochloride extended-release